Yahoo · Aug 12, 2026
European Equities Traded in the US as American Depositary Receipts Edge Lower in Wednesday Trading
European equities traded in the US as American depositary receipts were edging lower late Wednesday
AM
NASDAQ · AMRN
Amarin Corporation plc
Healthcare · Biotechnology
$14.09
Up+$0.03 (+0.21%)
Updated Aug 24, 2026, 8:37 AM
SID Score
3.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 285.42M
- P/E ratio
- -147.97
- Dividend yield
- 0.00%
- 52-week range
- $12.96 – $17.25
- Volume
- 36.56K
- Avg. volume
- 93.27K
Price performance
AMRN price history
1M range · 20 trading sessions · Daily adjusted prices
AMRN closed at $14.09 after 20 trading sessions, up 2.03% for the selected period.
- Last close
- $14.09
- Period change
- +2.03%
- Period low
- $13.81
- Period high
- $14.41
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $14.04 | $14.225 | $14.02 | $14.09 | 36.56K |
| Aug 20, 2026 | $14.22 | $14.355 | $14.05 | $14.06 | 31.5K |
| Aug 19, 2026 | $14.29 | $14.55 | $14.0921 | $14.38 | 59.91K |
| Aug 18, 2026 | $13.93 | $14.2336 | $13.90 | $14.13 | 52.97K |
| Aug 17, 2026 | $13.92 | $14.17 | $13.90 | $14.01 | 57.15K |
| Aug 14, 2026 | $14.02 | $14.145 | $13.92 | $14.07 | 52.51K |
| Aug 13, 2026 | $14.04 | $14.3033 | $14.015 | $14.15 | 51.57K |
| Aug 12, 2026 | $14.03 | $14.24 | $13.80 | $14.06 | 47.16K |
| Aug 11, 2026 | $14.12 | $14.25 | $13.975 | $14.01 | 45.17K |
| Aug 10, 2026 | $14.22 | $14.385 | $13.9564 | $14.11 | 35.06K |
| Aug 7, 2026 | $14.26 | $14.49 | $14.23 | $14.36 | 43.81K |
| Aug 6, 2026 | $14.42 | $14.60 | $14.24 | $14.26 | 23.75K |
| Aug 5, 2026 | $14.35 | $14.58 | $14.1001 | $14.41 | 29.95K |
| Aug 4, 2026 | $14.12 | $14.50 | $13.90 | $14.40 | 76.83K |
| Aug 3, 2026 | $14.28 | $14.28 | $13.80 | $14.14 | 84.15K |
| Jul 31, 2026 | $14.18 | $14.40 | $13.85 | $14.26 | 59.62K |
| Jul 30, 2026 | $14.13 | $14.34 | $14.0369 | $14.23 | 42.16K |
| Jul 29, 2026 | $13.98 | $14.55 | $13.76 | $14.16 | 63.07K |
| Jul 28, 2026 | $13.80 | $14.04 | $13.6684 | $13.95 | 65.67K |
| Jul 27, 2026 | $13.62 | $13.94 | $13.535 | $13.81 | 52.79K |
Latest AMRN news
The latest Smart Investors Daily articles mentioning AMRN.
Stock researchCompany · Overview
AMRN research
Overview
Company profile and research snapshot.
Company profile
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $2.17
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 21, 2026 | JP Morgan | Underweight | — |
| Jun 25, 2025 | Goldman Sachs | Sell | — |
| Apr 17, 2025 | Goldman Sachs | Sell | — |
| Jun 20, 2024 | Cantor Fitzgerald | Overweight | — |
| Jun 18, 2024 | Cantor Fitzgerald | Overweight | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 8, 2026
Amarin (AMRN) Q2 2026 Earnings Call Transcript
Amarin narrows losses while expanding global market reach across 22 countries.
SeekingAlpha · Jul 29, 2026
Amarin Corporation plc (AMRN) Q2 2026 Earnings Call Transcript
Amarin Corporation plc (AMRN) Q2 2026 Earnings Call July 29, 2026 8:00 AM EDTCompany ParticipantsDevin SullivanAaron Berg - CEO, President &...
ChartMill · Jul 29, 2026
Amarin Posts Surprise Q2 Profit on Cost Discipline, Shares Rise Pre-Market (NASDAQ:AMRN)
Amarin Q2 results: revenue miss at $42.2M but surprise $0.04 adjusted EPS beat. Cost cuts drive positive cash flow, shares up 1.7%.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
